ALK and non-small cell lung carcinoma: There are multiple HSP90 inhibitors in clinical development, extensively described in Rastogi’s paper [269], including ganetespib, which also induces ALK degradation, overcomes ALK resistance in NSCLC cells, and showed activity in NSCLC patient with prior crizotinib resistance [270].